WASHINGTON — A controversial Food and Drug Administration working group has begun discussing how to import drugs from other countries as a way of bringing down prices for American patients, a top Trump administration health official said Monday.
“That work group has met and is outlining its plan of action,” Dan Best, senior adviser on drug pricing, said on a phone call with reporters. “As more of that information becomes available, we’ll make it available to the market.”
The FDA announced the creation of the working group last month, saying it would consider policies to import off-patent drugs if the price increased drastically. The goal is to use importation to help lower prices for patients while competitors get into the market.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
